Clinical Trial Update: A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) [Phase 3]

View source ↗

Summary

A Phase 3 study of telaprevir in combination with Pegasys and Copegus in treatment-naive genotype 1 hepatitis C patients completed, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• Telaprevir (telaprevir)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2011-07-21